JP2005516035A5 - - Google Patents

Download PDF

Info

Publication number
JP2005516035A5
JP2005516035A5 JP2003561625A JP2003561625A JP2005516035A5 JP 2005516035 A5 JP2005516035 A5 JP 2005516035A5 JP 2003561625 A JP2003561625 A JP 2003561625A JP 2003561625 A JP2003561625 A JP 2003561625A JP 2005516035 A5 JP2005516035 A5 JP 2005516035A5
Authority
JP
Japan
Prior art keywords
melagatran
medicament
kit
pharmaceutically acceptable
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003561625A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005516035A (ja
Filing date
Publication date
Priority claimed from SE0200198A external-priority patent/SE0200198D0/xx
Application filed filed Critical
Publication of JP2005516035A publication Critical patent/JP2005516035A/ja
Publication of JP2005516035A5 publication Critical patent/JP2005516035A5/ja
Pending legal-status Critical Current

Links

JP2003561625A 2002-01-23 2003-01-21 I型糖尿病の処置に用いる医薬の製造のための、メラガトランの使用 Pending JP2005516035A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0200198A SE0200198D0 (sv) 2002-01-23 2002-01-23 New use
PCT/SE2003/000087 WO2003061682A1 (en) 2002-01-23 2003-01-21 The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus

Publications (2)

Publication Number Publication Date
JP2005516035A JP2005516035A (ja) 2005-06-02
JP2005516035A5 true JP2005516035A5 (https=) 2006-03-09

Family

ID=20286751

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003561625A Pending JP2005516035A (ja) 2002-01-23 2003-01-21 I型糖尿病の処置に用いる医薬の製造のための、メラガトランの使用

Country Status (14)

Country Link
US (2) US7045502B2 (https=)
EP (1) EP1469874A1 (https=)
JP (1) JP2005516035A (https=)
KR (1) KR20040075096A (https=)
CN (1) CN100430089C (https=)
BR (1) BR0306798A (https=)
CA (1) CA2472241A1 (https=)
IL (1) IL162853A0 (https=)
MX (1) MXPA04007192A (https=)
NO (1) NO20043483L (https=)
NZ (1) NZ533749A (https=)
SE (1) SE0200198D0 (https=)
WO (1) WO2003061682A1 (https=)
ZA (1) ZA200405342B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200198D0 (sv) * 2002-01-23 2002-01-23 Astrazeneca Ab New use
JP6155187B2 (ja) 2010-03-30 2017-06-28 ヴァーセオン コーポレイション トロンビンの阻害剤としての多置換芳香族化合物
HK1214252A1 (zh) 2013-03-15 2016-07-22 Verseon Corporation 作為凝血酶抑制劑的鹵代吡唑
CN110179795A (zh) 2013-03-15 2019-08-30 维颂公司 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物的制药用途
US10189810B2 (en) 2014-09-17 2019-01-29 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
CN107405333A (zh) 2015-02-27 2017-11-28 维颂公司 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物
CN113164765B (zh) 2018-07-13 2026-03-20 维颂国际公司 凝血酶抑制剂、制剂及其用途
JP2024535677A (ja) 2021-08-11 2024-10-02 サナ バイオテクノロジー,インコーポレイテッド 即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞
KR20240155390A (ko) 2022-02-17 2024-10-28 사나 바이오테크놀로지, 인크. 조작된 cd47 단백질 및 이의 용도
WO2024229302A1 (en) 2023-05-03 2024-11-07 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
CN121604968A (zh) 2023-05-22 2026-03-03 萨那生物科技公司 递送胰岛细胞的方法及相关方法
AU2024328949A1 (en) 2023-08-23 2026-03-12 Sana Biotechnology, Inc. Modified cd47 proteins and their uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
TWI238827B (en) 1995-12-21 2005-09-01 Astrazeneca Ab Prodrugs of thrombin inhibitors
SE9900070D0 (sv) * 1999-01-13 1999-01-13 Astra Ab New use
SE523817C2 (sv) 1999-02-05 2004-05-18 Corline Systems Ab Användning av ett koagulationsförebyggande ämne i samband med transplantation av insulinproducerande celler
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
SE0200198D0 (sv) * 2002-01-23 2002-01-23 Astrazeneca Ab New use

Similar Documents

Publication Publication Date Title
JP2005516035A5 (https=)
JP2004538303A5 (https=)
JP2005526107A5 (https=)
JP2006515587A5 (https=)
JP2008510691A5 (https=)
JP2005525369A5 (https=)
JP2006143737A5 (https=)
JP2009500423A5 (https=)
TW200528097A (en) Novel thiazolidin-4-one derivatives
JP2005526696A5 (https=)
CA2513092A1 (en) Compounds for the treatment of metabolic disorders
CA2522738A1 (en) Compounds for the treatment of metabolic disorders
JP2004517843A5 (https=)
CA2521621A1 (en) Compounds for the treatment of metabolic disorders
JP2008512408A5 (https=)
JPH08504201A (ja) 抗うつ作用を有する医薬組成物としての2‐アミノ‐6‐n‐プロピル‐アミノ‐4,5,6,7‐テトラヒドロベンゾチアゾールの使用
CA2621404A1 (en) Novel heterobicyclic derivatives
RU2004132856A (ru) Фармацевтический препарат с модифицированным высвобождением
JP2007507494A5 (https=)
JP2002519425A5 (https=)
JP2008534453A5 (https=)
JP2009517411A5 (https=)
CA2521589A1 (en) Compounds for the treatment of metabolic disorders
JP2006510658A5 (https=)
JP2004525178A5 (https=)